Description:

For more than a half-century, Canada has led the way internationally when it comes to the research, development and production of medical isotopes and radiopharmaceuticals. The world has counted on us, and the Canadian Nuclear Isotope Council was established to bring together all the stakeholders in the isotope industry with a mission to ensure we continue this leadership role in improving people’s lives.

The CNIC raises awareness and advocates for long-term policies that support innovation in healthcare and industry, and will improve countless lives for decades to come.

Canada is home to nearly the complete supply chain for multiple isotopes. Canadian companies supply the specialized equipment and the irradiation, processing, packaging, and transportation services necessary to produce a range of isotopes.

The Nuclear medicine market will grow 15% annually until 2026. By 2031, it is projected that the market will reach between $14 billion and $33 billion US

Canada is an emerging as a leader in the development and innovation of emerging isotopes; Lutetium-177 is now produced at commercial scale at Bruce Power in partnership with ISOGEN, SON, and ITM, Actinium-225, to treat a variety of cancers, to be produced by Actineer (CNL & ITM), Yttrium-90 production to be explored in OPG’s reactor (with Boston Scientific)

There are significant opportunities for Canada to double its production of isotopes by 2030 to meet growing global demand.

Approved for 1 Category A Credit